{
  "source": "PA-Notification-Sotyktu.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1402-3\nProgram Prior Authorization/Notification\nMedication Sotyktu™ (deucravacitinib)\nP&T Approval Date 1/2023, 7/2023, 7/2024\nEffective Date 9/1/2024\n1. Background:\nSotyktu is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with\nmoderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.\nLimitations of Use:\nNot recommended for use in combination with other potent immunosuppressants.\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\n1. Initial Authorization\na. Sotyktu will be approved based on both of the following criteria:\n(1) Diagnosis of moderate-to-severe plaque psoriasis\n-AND-\n(2) Patient is not receiving Sotyktu in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara\n(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx\n(secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya\n(tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Sotyktu will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Sotyktu therapy\n-AND-\n(2) Patient is not receiving Sotyktu in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara\n© 2024 UnitedHealthcare Services, Inc.\n1\n(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx\n(secukinumab), Taltz (ixekizumab), Siliq (brodalumab), Ilumya\n(tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan cover",
    "nib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits and/or Medical Necessity may be in place.\n4. Reference:\n1. Sotyktu [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; September 2022\nProgram Prior Authorization/Notification - Sotyktu (deucravacitinib)\nChange Control\n1/2023 New program\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n7/2024 Annual review. No changes.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}